Table 1.
All (n = 358) | CH (n = 137) | LC CP‐A (n = 169) | LC CP‐B/C (n = 52) | |
---|---|---|---|---|
Age, yearsa (SD) | 70.8 (10.2) | 70.8 (10.8) | 71.1 (9.3) | 69.8 (11.2) |
Gender, male:female* | 234:124 | 99:38 | 107:62 | 28:24 |
BMI, kg/m2 a (SD) | 23.4 (21.0–25.6) | 23.4 (3.5) | 23.6 (3.3) | 23.6 (3.8) |
Aetiology, HCV:HBV:HBV&HCV:Alcohol:others | 192:49:1:54:62 | 72:30:1:15:19 | 93:17:0:28:31 | 27:2:0:11:12 |
AST, IU/La (SD)** , **** | 40.0 (27.8) | 33.1 (22.6) | 40.1 (25.5) | 58.2 (37.9) |
ALT, IU/La (SD)* | 30.6 (24.2) | 26.8 (20.4) | 31.5 (26.4) | 37.3 (24.9) |
Platelets, 104/μLa (SD)** , *** | 14.1 (6.0) | 18.5 (5.0) | 11.8 (4.7) | 10.3 (5.0) |
Total bilirubin, mg/dLa (SD)** , **** | 0.98 (0.93) | 0.7 (0.3) | 0.9 (0.4) | 2.0 (2.0) |
Albumin, g/dLa (SD)** , *** , **** | 3.99 (0.61) | 4.28 (0.33) | 4.05 (0.52) | 3.08 (0.62) |
Prothrombin time, %a (SD)** , *** , **** | 84.7 (15.3) | 92.3 (10.6) | 84.3 (13.7) | 69.0 (16.5) |
History of HCC (%)**** | 228 (63.7) | 84 (61.3) | 121 (71.6) | 23 (44.2) |
TNM stage in HCC patients, none:I:II:III:IV | 266:25:37:14:16 | 102:11:12:4:8 | 124:12:18:8:7 | 40:2:7:2:1 |
HU by CTa (SD)** | 47.1 (5.0) | 47.5 (5.0) | 47.3 (4.8) | 45.4 (5.2) |
Frequency of finger‐circle test results, Bigger:Just‐fits:Smaller | 192:104:62 | 78:35:24 | 90:54:25 | 24:15:13 |
Frequency of MA, none:pre‐MA:MA | 179:121:58 | 68:47:22 | 87:57:25 | 24:17:11 |
Positive for handgrip strength decline (%)* | 152 (42.5) | 48 (35.0) | 75 (44.4) | 29 (55.8) |
With sarcopenia (%) | 30 (8.4) | 8 (5.8) | 14 (8.3) | 8 (15.4) |
ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; CH, chronic hepatitis; CP, Child–Pugh classification; CT, computed tomography; HBV, hepatitis B virus; HCC, hepatitis C virus; HCV, hepatitis C virus; HU, Hounsfield units; LC, liver cirrhosis; MA, muscle atrophy.
Mean value.
P < 0.05 between CH and LC CP‐B/C.
P < 0.01 between CH and LC CP‐B/C.
P < 0.01 between CH and LC CP‐A.
P < 0.01 between LC CP‐A and CP‐B/C (Bonferroni's method).